The field of cellular immunotherapy stands at an inflection point. While CAR-T therapies have achieved remarkable success in blood cancers, the expansion into solid tumors and other disease applications demands new approaches to understanding and controlling T cell behavior. The challenge extends beyond genetic engineering to a fundamental question: how do we predict and optimize how therapeutic T cells will interact with the complex tissue environments they must navigate in vivo?
In a comprehensive review published in Nature Reviews Bioengineering, authors Alapan and Thomas survey the landscape of microtechnologies and nanotechnologies being developed to engineer T cell interfaces—the physical and biological interactions that govern T cell function and fate. Notably, the review positions Adhesion Chromatography, Infiltrate Bio's foundational platform, as a key enabling technology spanning discovery optimization, manufacturing quality control, and translational biomarker development.
From Basic Biology to Therapeutic Manufacturing
T cells constantly communicate with their environment through interfaces at the cellular and tissue scales. These interactions (e.g. spanning T cell activation, vascular adhesion, tissue infiltration, and target cell engagement, etc.) can dictate whether a therapeutic product will succeed or fail in patients. Traditional characterization methods measure cells in isolation, providing snapshots of phenotype that often fail to predict in vivo performance.
The Nature Reviews Bioengineering article examines how engineered platforms can recapitulate these critical interfaces in vitro, enabling both mechanistic discovery and functional screening. Among the platforms discussed, adhesion chromatography stands out for its unique ability to model the hemodynamic forces and adhesive interactions that T cells encounter during tumor homing via the vasculature, a critical barrier to successful tumor infiltration.
Adhesion Chromatography: Function Over Phenotype
The review highlights how the adhesion chromatography platform addresses limitations inherent in conventional flow chambers and static assays. The platform's core capability, high-throughput functional sorting based on tissue homing capacity, is achieved by separating T cells based on their adhesion properties within the channels. Cells interacting strongly with the functionalized surface spend more time within the channel, while cells with low adhesive capacity flow freely and exit rapidly. This temporal separation permits collection of distinct populations for downstream profiling or adoptive transfer treatments.
Key findings cited in the review include:
- Enhanced tumor homing: CD8+ T cells sorted for P-selectin adhesion show significantly greater infiltration to solid melanoma tumors compared to their freely flowing counterparts and parent populations
- Functional biomarker discovery: Adhesion-enriched cells show increased expression of P-selectin ligand, CCR7, and LFA, yet tumor homing correlates with adhesive quality rather than specific T cell subtypes, demonstrating that functional assessment provides information phenotypic analysis alone cannot
- Adhesion profiling: CD8+ T cells with slow rolling characteristics possess greater selectin ligand expression regardless of naive, effector, or central memory classification
Translational Potential for Discovery, Manufacturing, and Beyond
Beyond mechanistic insights, the review emphasizes the translational opportunities for size-matching microsystems in therapeutic T cell manufacturing. The authors note that "bioinspired microsystems can recapitulate key biophysical properties of native cells and tissues, which might be exploited for the activation, expansion, screening and phenotype sorting of T cell products."
This positioning is particularly relevant to Infiltrate Bio's core applications. The adhesion chromatography platform serves multiple purposes:
- Discovery and optimization: Identifying cell features that confer superior homing, informing rational design of expansion protocols and genetic modifications
- Manufacturing quality control: Functionally testing cell products under physiological conditions to predict in vivo performance before clinical administration
- Translational Biomarkers: Establishing functional adhesion metrics that correlate with clinical outcomes to enable patient stratification and response prediction
Broader Context: A Field Maturing Toward Functional Characterization
The Nature Reviews Bioengineering article situates adhesion chromatography within a broader ecosystem of interfacial engineering approaches. This comprehensive framing underscores a field-wide recognition that traditional phenotypic markers provide incomplete information about therapeutic potential. Adhesion chromatography addresses a critical step in this cascade, providing data that cannot be obtained through any other commercially available technology.
Implications for Cell Therapy Development
For companies developing solid tumor cell therapies, this review validates what Infiltrate Bio has consistently emphasized: phenotype does not predict function. The gap between in vitro characterization and in vivo performance can only be bridged through functional testing under physiologically relevant conditions.
The platform's application to both mouse and human CD8+ T cells expanded using clinically relevant protocols demonstrates immediate translational relevance. As cell therapy developers face increasing pressure to de-risk programs, reduce development timelines, and improve patient response rates, functional adhesion testing offers a path forward grounded in fundamental biology.
As the field continues to evolve toward functional characterization, the ability to measure and predict infiltration will be essential to next-generation cell therapy development.
Learn more about how Infiltrate Bio's Adhesion Chromatography platform can transform your cell therapy development program: